488 related articles for article (PubMed ID: 19996339)
21. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
22. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
23. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
[TBL] [Abstract][Full Text] [Related]
25. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
26. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Ratjen F
Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
28. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.
Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G
Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185
[TBL] [Abstract][Full Text] [Related]
30. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
[TBL] [Abstract][Full Text] [Related]
31. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
Kernen Y; Sauty A; Roulet M
Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
[TBL] [Abstract][Full Text] [Related]
32. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Adeboyeku D; Jones AL; Hodson ME
J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
[TBL] [Abstract][Full Text] [Related]
33. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
34. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Elborn JS; Hodson M; Bertram C
J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
36. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
37. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
38. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
Nixon GM; Armstrong DS; Carzino R; Carlin JB; Olinsky A; Robertson CF; Grimwood K
J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046
[TBL] [Abstract][Full Text] [Related]
40. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
